Drug resistant MCF-7 cells have altered expression levels of ß-tubulin isotypes and mutations in TUBB gene

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi

Volumn 20, Issue 2, 2010, Pages 75-83

  Iseri, Ozlem D ^a,b   Kars, Meltem D ^a   Ufuk, Gunduz ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

tubulin isotypes; Antimicrotubule drugs; Multidrug resistance; Tubb

Indexed keywords

BETA TUBULIN; DOCETAXEL; MESSENGER RNA; PACLITAXEL; VINCRISTINE;

ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; EXON; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 77954653303     PISSN: 1306133X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Nogales E, Wolf SH, Downing K. Structure of the B- tubulin dimer by electron crystallography. Nature 391: 199-203, 1998.
2. Enju A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10: 665-685, 2005.
3. Clemons M, Leahy M, Valle J, et al. Clinical Oncology Update, Review of recent trials of chemotherapy for advanced breast cancer: The taxanes. Eur J Cancer 33: 2183-2193, 1997.
4. Kumar N. Taxol-induced polymerization of purified tu-bulin. Mechanism of action. J Biol Chem 256: 10435-10441 1981.
5. Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci 59: 1198-1211, 2002.
6. Wilson L, Jordan MA. Microtubule dynamics: Taking aim at a moving target. Chem Biol 2: 569-573, 1995.
7. Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10: 947-959, 1999.
8. Huzil JT, Luduena FD, Tuszynski J. Comparative modeling of human B tubulin isotypes and implications for drug binding. Nanotechnology 17: S90-S100, 2006.
9. Banerjee A, Roach MC, Trcka P, Luduena RF. Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin. J Biol Chem 265: 1794-1799, 1990.
10. Luduena RF. Multiple forms of tubulin: Different gene products and covalent modifications. Int Rev Cytol 178: 207-275, 1998.
11. Bhattacharya R, Cabral F. A ubiquitous B-tubulin distrupts microtubule assembly and inhibits cell proliferation. Mol Biol Cell 15: 3123-3131, 2004.
12. Drukman S, Kavallaris M. Microtubule alterations and resistance to tubulin-binding agents (Review). Int J Oncol 21: 621-628, 2002.
13. Verdier-Pinard P, Wang F, Martello L, et al. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Biochem 42: 5349-4357, 2003.
14. Hari M, Yang H, Zeng C, et al. Expression of class III B-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskel 56: 45-56, 2003.
15. Liu B, Staren E, Iwamura T, et al. Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines. World J Gastroenterol 7: 855-859, 2001.
16. Banerjee A. Increased levels of tyrosinated B-, BIII-, and BIV-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cell. BBRC 293: 598-601, 2002.
17. Hasegawa S, Miyoshi Y, Egawa C, et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 9: 2992-2997, 2003.
18. Shalli K, Brown I, Heys SD, Schofield AC. Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 10: 1299-1301, 2005.
19. Kavallaris M, Dennis Y, Kuo S, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific B-tubulin isotypes. J Clin Invest 100: 1282-1293, 1997.
20. Kavallaris M, Tait AS, Walsh BJ, et al. Multiple micro- tubule alterations are associated with vinca alkaloid resistance in human leukemia cells. Cancer Res 61: 5803-5809, 2001.
21. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant be-ta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118-17125, 1997.
22. Hasegawa S, Miyoshi Y, Egawa C, et al. Mutational analysis of the class I beta-tubulin gene in human breast cancer. Int J Cancer 101: 46-51, 2002.
23. Wiesen KM, Xia S, Yang CH, Horwitz SB. Wild-type classI b-tubulin sensitizes Taxol-resistant breast adeno carcinoma cells harboring a b-tubulin mutation. Cancer Lett 257: 227-235, 2007.
24. Kars M.D, Iseri OD, Gunduz U, et al. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 26: 4559-4568, 2006.
25. Bacus SS, Kiguchi K, Chin D, et al. Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol Carcinogen 3: 350-362, 1990.
26. Iseri OD, Kars MD, Eroglu S, Gunduz U. Cross-resistance Development and Combined Applications of An-ticancer Agents in Drug Resistant MCF-7 Cell Lines. UHOD 1: 1-8, 2009.
27. Chomczynski PS. Single step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
28. Cobley JG, Clark AC, Weerasurya S, et al. CpeR is an activator required for expression of the phycoerythrin operon (cpeBA) in the cyanobacterium Fremyella dip-losiphon and is encoded in the phycoerythrin linker-polypeptide operon (cpeCDESTR). Mol Microbiol 44: 1517-1531, 2002.
29. Kars G, Gunduz U, Yucel M, et al. Hydrogen production and transcriptional analysis of nifD, nifK and hupS genes in Rhodobacter sphaeroides O.U.001 grown in media with different concentrations of molybdenum and iron. Int J Hydrogen Energ 31: 1536-1544, 2006.
30. Young AM, Allen CE, Audus KL. Efflux transporters of the human placenta, Adv Drug Deliver Rev 55: 125-132, 2003.
31. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents. Microtubule dynamics, drug transport and cell death. J Clin Oncol 17: 10611070, 1999.
32. Burkhart CA, Kavallaris M, Horwitz SB. The role of b-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 1471: 1-9, 2000.
33. Derry WB, Wilson L, Khan IA, et al. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry 36: 3554-3562, 1997.
34. Panda D, Miller HP, Banerjee A, et al. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci USA 91: 11358-1362, 1994.
35. Bernard-Marty C, Treilleux I, Dumontet C, et al. Micro-tubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: Results of a pilot study. Clin Breast Cancer 3: 341-345, 2002.
36. Lu, Q, Luduena RF. Removal of beta III isotype enhances taxol induced microtubule assembly. Cell Struct Funct 18: 173-182, 1993.
37. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oli-gonucleotides to class III B-tubulin sensitize drug-resistant cells to Taxol. Brit J Cancer 80: 1020-1025, 1999.
38. Verdier-Pinard P, Shahabi S, Wang F, et al. Detection of human betaV-tubulin expression in epithelial cancer cell lines by tubulin proteomics. Biochemistry 44: 15858-15870, 2005.
39. He L, Huang Yang CP, Horwitz SB. Mutations in b-Tu-bulin map to domains involved in regulation of micro-tubule stability in epothilone-resistant cell lines. Mol Cancer Ther 1: 3-10, 2001.
40. Rao S, Krauss NE, Heerding JM, et al. 3'-(p-azidoben-zamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem 269: 3132-3134, 1994.
41. Snyder JP, Nettles JH, Cornett B, et al. The binding conformation of Taxol in b-tubulin: A model based on electron crystallographic density. Proc Natl Acad Sci USA 98: 5312-5316, 2001.
42. Sale S, Sung R, Shen P, et al. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resis- tant ovarian cancers. Mol Cancer Ther 1: 215-225, 2002.
43. Dozier JH, Hiser L, Davis JA, et al. Beta class II tubu- lin predominates in normal and tumor breast tissues. Breast Cancer Res 5: 157-169, 2003.